This report was first published by Endpoints News. To see the original version, click here
Sarepta said the effects of its Duchenne muscular dystrophy gene therapy were durable three years after treatment, based on longer-term findings from patients in its key clinical trial.
The data come after a tumultuous year for Sarepta and its gene therapy Elevidys, in which there were two patient deaths due to the one-time treatment.
您已阅读17%（425字），剩余83%（2008字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。